Cross-Sector entity
5th U.S. Circuit Court of Appeals is the most frequent co-covered peer, appearing in 6 of the 6 tracked stories. Coverage clusters in fda-approval, which accounts for 2 of those 6, with the remainder spread across 3 other categories. Each carries 2 original sources on average.
6 verified stories tracked
Last mentioned: Sep 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
5th U.S. Circuit Court of Appeals is the most frequent co-covered peer, appearing in 6 of the 6 tracked stories. Coverage clusters in fda-approval, which accounts for 2 of those 6, with the remainder spread across 3 other categories. Each carries 2 original sources on average. Negative sentiment appears in 50% of the tracked stories. Rosalie Markezich appears in 6 tracked Cross-Sector stories published from September 9, 2026 through September 12, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rosalie Markezich. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
Medication abortion using mifepristone and misoprostol is now the standard of care for most US abortions. A 5th Circuit ruling could disrupt telehealth prescribing and shield-law access for 770 to 900 Louisiana women each month. The FDA's concurrent safety review adds clinical-policy uncertainty.
Source: nbcsandiego.com · nbcwashington.com
A Fifth Circuit panel is weighing whether federal courts or the FDA should govern mifepristone prescribing, with state shield laws and cross-border pill access at issue. The case is one of three appeals seeking to restrict medication abortion.
Medication abortion accounts for at least 60% of U.S. abortions, and a lawsuit could restrict mifepristone prescribing in states where abortion is legal. Clinicians and telehealth providers face uncertainty over cross-border prescriptions and FDA rules.
For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Source: MedPage Today · chicagotribune.com
Healthcare providers and health IT teams face potential disruption as the 5th Circuit weighs barring telehealth prescribing of mifepristone. Survey data show 770-900 Louisiana women per month used pills prescribed online or by out-of-state clinicians in 2025.
The biopharmaceutical sector is watching the 5th Circuit review of mifepristone's FDA prescribing rules. At least 60% of U.S. abortions use the two-drug regimen, making the drug's distribution and label conditions a high-stakes regulatory precedent.
Source: timesargus.com · bozemandailychronicle.com
